Ticker

Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) is expected to release its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect Oncolytics Biotech to post earnings of ($0.06) per share for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call

Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate material dilution SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that it…

/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies

Oncolytics Biotech Inc. (NASDAQ: ONCY - Get Free Report)'s share price rose 1.3% on Wednesday. The company traded as high as $0.86 and last traded at $0.8535. Approximately 1,728,312 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 1,843,999 shares. The stock had previously closed at $0.8422. Analyst

/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency